All News

Lungs ILD

Increased Mortality In Arthritis Patients with COPD

EurekAlert!

People with chronic obstructive pulmonary disease (COPD) and arthritis have a higher risk of death than people with arthritis who do not have COPD, according to a new study.

Read Article
syringe, pill, DMARD, Treatment, therapy

Are Combination Biologics Safe?

Jack Cush, MD

Although package inserts commonly warn against combining the use of biologic or targeted therapies, there is growing interest in such combination therapy for patients with problematic immune-mediated inflammatory diseases (IMID).

Read Article
RheumNow Podcast square

Hydroxychloro-King (3.7.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and regulatory actions from the past week on RheumNow.com

Read Article
microbiome,blue

Crohn’s Microbiome may Predispose to Axial Spondyloarthritis

EurekAlert!

People with Crohn’s disease and related joint inflammation linked to immune system dysfunction have distinct gut bacteria or microbiota, with the bacterium Mediterraneibacter gnavus being a potential biomarker, according to new study by Weill Cornell Medicine researchers.

Read Article
AI,genes

SOCS1 Insufficiency - a Rare Inborn Error of Immunity

Jack Cush, MD

Lancet Rheumatology has published a population study of the rare suppressor of cytokine signalling 1 (SOCS1) insufficiency - an inborn error of immunity affecting the negative regulation of cytokine and growth factor signalling.

Read Article
ankle.fusion.medpage

Ankle Fusion or Total Replacement?

Jack Cush, MD

In a large study of British patients needing surgical treatment for advanced arthritis in the ankle, fusion appeared to be a better option than total ankle replacement.

Read Article
AI,genes

Diagnoses via Immune ‘Fingerprints’

Jack Cush, MD

Science and researchers at Stanford Medicine have reported the use of Mal-ID (machine learning for immunological diagnosis) to analyze B and T cell receptors sequences from human blood, showing the ability to predict health status (healthy vs diseased) and discriminate between distinct autoimmune diseases or viral infections, and those who had received an influenza vaccine.

Read Article
Meta-analysis shows the combination therapy bDMARD with MTX in #PsA pts yields better bDMARDs drug survival, especially with TNFi. 20 observational studies, 30,634 PsA pts. Insufficient data for non-TNFi bDMARDs. But adding MTX to bDMARDs had better TNFi survival (HR=0.79… https://t.co/3Y2cOzt3TQ https://t.co/6f8yiwMqAa
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of cancer risk w/ abatacept vs placebo or TNFi in #RA. (18 RCTs, 10 LTE, 15 535 PYs ABA exposure) show no signif increase in malignancy for ABA vs PBO (IRR 0.58) or TNFi (IRR 0.72). Observational data ABA > other b/tsDMARDs (IRR 1.21; 1.15–1.28), but not csDMARDs… https://t.co/2aBfwyKv0e https://t.co/zUmaHZN3mR
Dr. John Cush RheumNow ( View Tweet)
DANBIO registry study - 21 982 Rx Starts, 96 475 PYs & 1423 cancers identified. Overall cancer risk w/in tocilizumab/sarilumab, abatacept or rituximab were not signif increased (HRs ranged from 0.7 to 1.1) compared with TNFi & with bDMARD-naïve real world RA pts… https://t.co/fPLFlWoQsw https://t.co/4KlGnjfNKm
Dr. John Cush RheumNow ( View Tweet)
BMS announced new data from Phase 3 POETYK PsA-2 trial - Sotyktu (deucravacitinib)vs apremilast vs PBO in PsA w/ higher ACR20 vs PBO at Week 16 (54% vs 39%). AEs led to discontinuation in 1.3% (PBO), 2.2% (Deuc) and 10.5% (apremilast). https://t.co/NAa2JigkZN https://t.co/mvaQXfjShd

Links:

Dr. John Cush RheumNow ( View Tweet)
Polypharmacy (>=5Rx) studied in 81 RA & 30 SLE pts. Polypharmacy incr at 2 yrs ~44% to ~73%. Med adherence >85%. Polypharmacy NOT assoc w/ Dz activity in SLE, but in RA did correlate w/ better DAS28CRP score at one year https://t.co/Jw05DIrBym https://t.co/pLIoDvPj8i

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 376 studies, 347 468 pts w/ chronic pain (mean 51yrs; 70%F) finds ~40% had clinically significant depression and anxiety (more common in Women, younger people, pts w nociplastic pain). Depression common in FM (54%) & OA/RA (~28%). https://t.co/s1tcgC3y7k https://t.co/NCxkOA82jD

Links:

Dr. John Cush RheumNow ( View Tweet)
Available the first time: https://t.co/4UQlqwujiR 2025 On Demand! On Demand gives you access to all lectures, Q & A panels, and STEP talks, and all speaker slides and handouts — all packed with insights you won’t find anywhere else. Non-CME, practical, and finally here.… https://t.co/MHFUWb3az1 https://t.co/cqzZG40Xp5

Links:

Dr. John Cush RheumNow ( View Tweet)
Risk of Cancer on JAKi in RA (12 463 vs 38 345 controls). No incr risk of CA w/ exposure to JAKi (adj OR 1.04), TNFi (0.98), other bDMARDs (0.98). But JAKi was assoc w/ signif more lung CA (1.40; esp in males 2.12) & less breast CA (0.62) in women https://t.co/fr3VjPhJve https://t.co/zNehdWBbeI

Links:

Dr. John Cush RheumNow ( View Tweet)
Selective mutation of Traf1/cIAP2 (V196) interaction attenuates inflammatory responses that may contribute to rheumatoid arthritis activity. THis may lead to a new class of therapies for RA https://t.co/kYqAqGsSEA https://t.co/JWUN6iTvxa

Links:

Dr. John Cush RheumNow ( View Tweet)
I ALWAYS recommend paraffin wax baths for stiffness, RA, OA, PSS, etc. Here are some instructions for home use https://t.co/CTI4K2kHf9 https://t.co/i0kO99vdYc

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospect. study of 77 RA pts w/ +ANCA (age 62 yrs, 79%F. 65% RF+. 45% p-ANCA+; 42% MPO+. Diagnoses included: AAV (29%); GPA (45%), MPA (36 %); EGPA (5%). Renal (41%) & upper Resp (36%) were most freq. Pts w/ RA+AAV had more RF, MPO+, nodules, inflam eye Dz… https://t.co/NTvAhZY2y8 https://t.co/IAkWHtcTCo
Dr. John Cush RheumNow ( View Tweet)
Optimal Management of Rheumatoid Arthritis Patients and Liver Disease https://t.co/4JfUueF55o https://t.co/hBkgYU1Mye

Links:

Dr. John Cush RheumNow ( View Tweet)
B Cell Depleters (2.21.2025) Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow. https://t.co/PRjy4a1BG9 https://t.co/3J4NSmn6Su

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×